NXS Stock Overview
Next Science Limited, a medical technology company, researches, develops, and commercializes technologies that address the impacts of biofilms in human health in the United States and Australia.
Next Science Limited Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.94|
|52 Week High||AU$1.55|
|52 Week Low||AU$0.70|
|1 Month Change||13.25%|
|3 Month Change||5.62%|
|1 Year Change||-38.16%|
|3 Year Change||-63.71%|
|5 Year Change||n/a|
|Change since IPO||-30.37%|
Recent News & Updates
|NXS||AU Medical Equipment||AU Market|
Return vs Industry: NXS underperformed the Australian Medical Equipment industry which returned -17.5% over the past year.
Return vs Market: NXS underperformed the Australian Market which returned -8.1% over the past year.
|NXS Average Weekly Movement||11.6%|
|Medical Equipment Industry Average Movement||11.5%|
|Market Average Movement||10.5%|
|10% most volatile stocks in AU Market||17.8%|
|10% least volatile stocks in AU Market||4.6%|
Stable Share Price: NXS is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: NXS's weekly volatility (12%) has been stable over the past year.
About the Company
Next Science Limited, a medical technology company, researches, develops, and commercializes technologies that address the impacts of biofilms in human health in the United States and Australia. The company develops its products using Xbio Technology platform. It offers SURGX, an antimicrobial gel designed for surgical infection management; BACTISURE, a wound lavage that is used to remove biofilm; BlastX, an antimicrobial wound gel that destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment; and XPERIENCE, an no rinse antimicrobial solution that helps prevent surgical site infections.
Next Science Limited Fundamentals Summary
|NXS fundamental statistics|
Is NXS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|NXS income statement (TTM)|
|Cost of Revenue||US$2.01m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.044|
|Net Profit Margin||-104.49%|
How did NXS perform over the long term?See historical performance and comparison